Digital for Pharma
1.6K views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Claudio Bini
Scoop.it!

PinUp: FDA vs. Deceptive Drug Ads, Pharmaguy's Social Media Compendium, Novartis & Pfizer Mobile Apps, More...

PinUp: FDA vs. Deceptive Drug Ads, Pharmaguy's Social Media Compendium, Novartis & Pfizer Mobile Apps, More... | Digital for Pharma | Scoop.it
Welcome to the January 10, 2017, edition of Pharma Industry News Update (aka PinUp), which is published every Tuesday and Thursday as part of the Pharma Marketing News subscription service. PinUp presents selected content of topical interest from a variety of sources. View the Web version of this issue here: http://bit.ly/PINUP011017 or by clicking here: http://preview.mailerlite.com/q7a8l9

Articles in this issue:“Re: Deceptive Drug Ads, Whose Opinion Does FDA Value More - HCPs or Consumers?”; http://sco.lt/91FW0P“PharmaGuy's Social Media Compendium ”; http://bit.ly/pgsoccat“Novartis Heart Partner Mobile App Aids Heart Failure Care Coordination”; http://sco.lt/7oVVon“Pfizer Shuns "Next Shiny Thing" When Developing Mobile Health Apps”; http://sco.lt/9CtktV
Further Reading:Another FDA Study: Can HCPs and Consumers Recognize "Deceptive" Drug Website Promotions; http://sco.lt/4pOskbFDA's BadAd CE Program: There Should Be An App for This!; http://sco.lt/6GvMobPharmaguy’s Gallery of FDA Studies of DTC Advertising; http://bit.ly/DTCstudyGalleryDisruptive Digital Technology News & Views; http://www.scoop.it/t/pharmaguy-s-social-media-news-viewsNovartis Launches Together in HF, the First Heart Failure Social Network by a Pharma Company; http://sco.lt/5Gee5RNovartis, Queen Latifah, & American Heart Association Team Up on Facebook Live Broadcast; http://sco.lt/6caCxNNovartis Tries Celebrity Disease Awareness Social Media Campaign to Boost Entresto Sales; http://sco.lt/93vmvxPfizer Joins the #Pharma Digital Accelerator Club: Offers $250,000 in Prize Funding for Metastatic Breast Cancer "Disruptive" Technology!; http://sco.lt/6PtsTRPfizer and IBM Join the Parkinson's Disease "Internet Of Things" Club; http://sco.lt/7xdDP7
---------------
Featured Survey
Direct-to-Consumer Off-Label Drug Promotion Survey
https://www.surveymonkey.com/r/8ZV5ZXQ

This survey solicits your opinion possible FDA future decisions regarding off-label drug promotion to patient and consumer audiences. CLICK HERE to take the survey: https://www.surveymonkey.com/r/8ZV5ZXQ
more...
No comment yet.
Rescooped by Claudio Bini from HEALTHCARE & SOCIAL MEDIA
Scoop.it!

The Value of Social Media in Academic Medicine: What are the data?

In this video, Jay Widmer, M.D., Ph.D., Interventional Cardiology Fellow at Mayo Clinic, discusses the value of social media in academic medicine.

Via Plus91, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Rescooped by Claudio Bini from Pharma Marketing News, Views & Events
Scoop.it!

Dear Patient, Come to the "Dark Side" & Engage with Pharma

Dear Patient, Come to the "Dark Side" & Engage with Pharma | Digital for Pharma | Scoop.it

Speaking at an industry conference, Dr. Anne Beal, Chief Patient Officer, at Sanofi, said "Patients can help in many ways and we (pharma) have to reach out to them all," to which @TuLupus -- a Spanish Lupus patient blogger on Twitter said "patients, don't be afraid of going to the 'dark side' - engage with pharma and industry (is not so dark)."

 

Dark side? Let's imagine Pharma as Darth Vader and patients like @TuLupus as Luke Skywalker:

 

Darth Vader: Luke, you do not yet realize your importance. You have only begun to discover your power. Join me, and I will complete your training. With our combined strength, we can end this destructive conflict and bring order to the galaxy.

 

[Here Pharma -- as Darth Vader -- is telling Luke -- who represents all patients but especially "ePatients" like @TuLupus -- that patients are just beginning to discover their power and if they join with pharma their power will be much greater. The combined strength of patients and pharma will bring order to the healthcare system.]

 

How does “Luke,” the patient, respond? Find out here.

 

Further reading/listening:

“Anne Beale Discusses The Three Pillars of Sanofi's Patient-Centric Strategy”: http://sco.lt/6nX5AP“Flowchart: How Pharma Can Handle Every Type of Comment on Social Media”: http://sco.lt/6tsLa5
Via Pharma Guy
more...
No comment yet.
Rescooped by Claudio Bini from Digital Disruption in Pharma
Scoop.it!

The mHealth App Gap

The mHealth App Gap | Digital for Pharma | Scoop.it

Several market forces are converging that boost patients’ ability to engage in their health and self-care, including peoples’ growing adoption of smartphones, demand for self-service and DIY lifestyles, and Americans’ growing responsibility as health consumers. Health consumers are using a growing array of self-health tools, enabled through digital technologies. However, these tools aren’t yet engaging some of the very people who need them the most: high-need, high-cost patients.

Research into this situation is discussed in the December 2016 Health Affairs article, Many Mobile Heaath Apps Target High-Need, High-Cost Populations, But Gaps Remain, published in the December 2016 issue of Health Affairs. For context, this research focuses solely on mobile health apps, and not the larger topics of telehealth and remote health monitoring.

The team of researchers span several institutions,  including the University of Michigan Medical School in Ann Arbor, Brigham and Women’s Hospital in Boston, and the Asan Medical Center in Seoul, Korea. The team mined mHealth apps in the iTunes  and Google Play stores in February 2015. In addition, they searched medical special society websites for additional apps, as well as recommendations from experts in the field. To narrow down the apps for the high-cost, high-need patient population, the researchers focused on many search terms of common chronic conditions (e.g., alcohol, asthma, bipolar, heart disease, diabetes, obesity, smoking, and stroke among them). The group focused in on 166 apps targeting the vulnerable study population of high-need, high-cost patients.

The team found the following:

Apps do exist and most track patient data. However, many lack functionality beyond tracking, such as providing personalized guidance, support through social networks, or rewarding behavior change.App store ratings correlate poorly with clinical utility and vary widely in terms of usability.Apps often do not react to dangerous information; only 23% responded appropriately when information indicated a health danger, like suicidal risk, emerged.Privacy policies and secure data-sharing is lacking across the range of apps studied.
Via Pharma Guy
more...
Pharma Guy's curator insight, December 8, 2016 7:12 AM

Related articles:

Rescooped by Claudio Bini from Digital for Pharma
Scoop.it!

FDA Compliant Diclegis Instagram Promo by (Good) Emily Maynard Johnson Can't Compete with (Bad) Kim Kardashian's Violative Post

FDA Compliant Diclegis Instagram Promo by (Good) Emily Maynard Johnson Can't Compete with (Bad) Kim Kardashian's Violative Post | Digital for Pharma | Scoop.it

About 22 weeks ago, Emily Maynard Johnson, who appeared on ABC's The Bachelor and The Bachelorette, posted a Diclegis promotion to her Instagram account (see above).I assume you've noticed that all the ISI (Important Safety Information) and side effects are mentioned either through links or, more importantly, within the post itself (you have to scroll down to see it).This is in contrast to Kim Kardashian's Diclegis Instagram promotion that made news last year. That ad drew a prompt warning letter from the FDA to Duchesnay USA, which markets the drug, because the post did not mention nor did it link to any ISI or side effect information as required by FDA regulations (for more on that read "OMG. Kim Kardashian Shills for Pharma! No Worry - No Side Effects!" and "Celebrities + Social Media"). There are a couple of other important differences between these two celebrity Instagram endorsements/ads.


Via Pharma Guy, Claudio Bini
more...
No comment yet.
Rescooped by Claudio Bini from Digital Disruption in Pharma
Scoop.it!

How #Pharma Uses Social Media - For Advertising, Not So Much. Duh! #infographic

How #Pharma Uses Social Media - For Advertising, Not So Much. Duh! #infographic | Digital for Pharma | Scoop.it

New communications technology has the potential to both disrupt and enhance the pharmaceutical industry, but research shows that pharma often needs to up its game when it comes to the adoption of new technologies.

Mobile devices have transformed how we access and consume content, and are poised to make similarly huge changes to the way consider our health (read “The mHealth App Market is at the Saturation Point”; http://sco.lt/5thWGv). mHealth revenue is projected to reach 26 billion by 2017, and the number of health apps has doubled in just the past two years. Social is also likely to have a major impact in the way that pharma communicates in the coming years. 52% of physician’s surveyed by Deloitte in this research expressed interest in communicating with pharma companies via social media.

However, pharma currently lags behind other verticals for using social media. Pharma spending on digital advertising is far below that of other industries, and it still conducts most of it’s communications with physicians via traditional channels. There is big potential for new communications technology to make the pharmaceutical industry more efficient and more engaged with it’s customers. This infographic from Deloitte shows the potential for new digital technology to allow pharma to market itself more effectively.


Via Pharma Guy
more...
No comment yet.
Rescooped by Claudio Bini from PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
Scoop.it!

IBM Watson & Celgene Partner to Bring Pharmacovgilance Into the Modern "Smart" Digital Era!

IBM Watson & Celgene Partner to Bring Pharmacovgilance Into the Modern "Smart" Digital Era! | Digital for Pharma | Scoop.it

Celgene and IBM are teaming up on a new patient safety monitoring platform to improve pharmacovigilance methods throughout the drug development process.

The platform, dubbed IBM Watson for Patient Safety, will combine Watson’s cognitive computing chops with Celgene’s extensive experience in drug safety and risk management. It will be an outcome- and evidence-based drug safety decision support system for life sciences companies, the duo said in a statement.

It will run on the Watson Health Cloud. The highly automated, modular, end-to-end drug safety platform will allow for the rapid collection, collation and automated analysis of vast amounts of data from a variety of sources, the companies said in a statement. It will help biopharmaceutical companies better manage and interpret large volumes of data relating to potential side effects associated with drug products, they said.

“For a long time, very big decisions around the use and disposition of drugs have been taken based on small datasets,” said John Freeman, corporate vice president of global drug safety and risk management at Celgene. “This is an opportunity to not only streamline the way that information is handled within pharma companies and regulators, but also to enable much greater clarity of insight born of an ability to access large datasets.”

IBM Watson for Patient Safety will use cognitive computing to understand structured and unstructured language and therefore use a lot of different sources to help in making decisions, said Lauren O’Donnell, vice president of life sciences at IBM Watson Health. These include anonymized electronic medical records and medical claims databases. In addition to analyzing and identifying trends in large datasets, IBM Watson also learns. And the case numbers are only continuing to grow: Between 2008 and 2011 alone, there was a 90% increase in serious adverse events recorded, she said.

While the obvious applications are for decision-making in the early stages of drug development, leading to greater efficiencies while developing products, there are also advantages post-commercialization, Freeman said. The platform can help patients who are at greater risk of side effects manage their condition better and reduce the likelihood of those side effects.

“Celgene established one of the first risk management systems and its commitment to pharmacovigilance continues with this partnership,” O’Donnell said in the statement. “Together we look forward to creating a cognitive solution that can be applied across the industry to help benefit patients everywhere.”


Via Pharma Guy, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Rescooped by Claudio Bini from PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
Scoop.it!

#FDA Publishes New Draft Guidance on Software as a Medical Device (SaMD).

#FDA Publishes New Draft Guidance on Software as a Medical Device (SaMD). | Digital for Pharma | Scoop.it

The FDA has entered into the federal register a new draft guidance pertaining to "software as a medical device" (SaMD). The guidance is presented as representing the FDA's current thinking on establishing clinical evaluation guidelines for SaMD, but is written by an international organization of device regulators, the International Medical Device Regulators Forum, of which FDA is a member.

The guidance seeks to articulate what's new and different about SaMD (a category which would include mobile medical apps) and provide a stratified guidance on how to regulate different kinds of software and what kind of evidence is needed for each regulatory category. The guidance stratifies devices on two axes: whether the device informs care, drives care, or treats/diagnoses and whether the condition in question is non-serious, serious, or critical. So software that treats or diagnoses a critical condition is in the highest risk category, while software that informs care about a non-serious condition is in the lowest.

The guidelines also call out and address the fact that software development tends to move faster than traditional medical device development and can more easily be influenced by postmarket data.

"SaMD ... is unique in that it operates in a complex highly connected-interactive socio-technical environment in which frequent changes and modifications can be implemented more quickly and efficiently," the guidance says. "Development of SaMD is also heavily influenced by new entrants unfamiliar with medical device regulations and terminology developing a broad spectrum of applications."


Via Pharma Guy, Lionel Reichardt / le Pharmageek
more...
Pharma Guy's curator insight, October 18, 2016 7:26 AM

Related article: “Is SaaD - Software as a Drug - the Next Big Thing in mHealth?”; http://sco.lt/7SITsv

rob halkes's curator insight, October 18, 2016 7:39 AM

Via @pharmaguy The New #FDA draft guidance on software as a Medical Device (SaMD)

Rescooped by Claudio Bini from Pharma Communication & Social Media
Scoop.it!

Nestle, Samsung to develop digital health platform

Nestle, Samsung to develop digital health platform | Digital for Pharma | Scoop.it

Nestle and Samsung have announced a research collaboration that will see the world's largest food maker team up with the Korean tech giant to explore the potential of nutrition science and digital sensor technologies. The long-term goal of the collaboration is to combine 'Internet of Things' technology with "breakthrough nutrition science". The companies are developing a new digital health platform to provide personalised recommendations around nutrition, lifestyle and fitness. Nestle and Samsung said their aim is to "empower people" to better manage their health and wellness using "one simple, connected entity".


Via Dinesh Chindarkar
more...
No comment yet.
Rescooped by Claudio Bini from PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
Scoop.it!

Report: 3 tips for pharma to provide beyond-the-pill services

Report: 3 tips for pharma to provide beyond-the-pill services | Digital for Pharma | Scoop.it

Physicians expect pharmaceutical companies to provide more beyond-the-pill services, as they face increasing pressure from empowered patients as well as accountable care organizations and integrated delivery networks, according to a new report.


Via Dinesh Chindarkar, Philippe Marchal, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Rescooped by Claudio Bini from Pharma Marketing
Scoop.it!

How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA

How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA | Digital for Pharma | Scoop.it
“After a Facebook PR meltdown two years ago, Sanofi has emerged as a social media leader with a robust community for diabetics. Here's how the”
Via COUCH Medcomms
more...
No comment yet.
Rescooped by Claudio Bini from Pharmaguy's Insights Into Drug Industry News
Scoop.it!

Life expectancy vs. health expenditure over time, 1970-2014

Life expectancy vs. health expenditure over time, 1970-2014 | Digital for Pharma | Scoop.it

The following graph visualizes the relationship between life expectancy and health expenditure, for a number of OECD countries across the period 1970-2014. Two points are worth mentioning. Firstly, all countries in this graph have followed an upward trajectory (life expectancy increased as health expenditure increased), but the U.S. stands out as an exception following a much flatter trajectory; gains in life expectancy from additional health spending in the U.S. were much smaller than in the other high-income countries, particularly since the mid-1980s. And secondly, the gains for all countries (except for the U.S.) were not diminishing, as in the previous graph. This suggests that there are many other factors affecting life expectancy, that are not determined by healthcare spending. Indeed, as we have pointed out before, healthcare is just one of many inputs to produce health.here to edit the content


Via Giuseppe Fattori, Pharma Guy
more...
Jeff French's curator insight, August 11, 2016 3:39 AM
Its not just how much you spend
Alex O. Awiti's curator insight, August 12, 2016 12:27 AM
Public investments in healthcare matter!
Scooped by Claudio Bini
Scoop.it!

Social Media Has Unrealized Potential for Clinical Trial Communication and Recruitment

Social Media Has Unrealized Potential for Clinical Trial Communication and Recruitment | Digital for Pharma | Scoop.it
The social media platform Twitter could develop into a useful tool for communicating with the public about cancer clinical trials and for recruiting participants.
more...
No comment yet.
Rescooped by Claudio Bini from Pharma Marketing News, Views & Events
Scoop.it!

Igea: Pharma Marketing Blog is #4 of Top 10 Pharma Blogs in 2016

Igea: Pharma Marketing Blog is #4 of Top 10 Pharma Blogs in 2016 | Digital for Pharma | Scoop.it

Pharmaceutical industry is renowned for innovation. New drugs are continuously being discovered and marketed around the world. Furthermore, new mergers and acquisitions are happening in the pharmaceutical industry on a regular basis, and new studies are being conducted quite regularly by the pharma companies. Hence, if you want to keep yourself updated with the latest developments in this industry, then you need to follow the top pharma blogs which are informative and helpful. This article will shed some lights on the top 10 pharmaceutical blogs that are must read for every person who is interested in the pharma industry, particularly for every pharma professional. These blogs attract a lot of online traffic per month.


Via Pharma Guy
more...
No comment yet.
Rescooped by Claudio Bini from Digital Disruption in Pharma
Scoop.it!

eMarketer Slashes Growth Outlook for Wearables - Only Early Adopters are Using Them

eMarketer Slashes Growth Outlook for Wearables - Only Early Adopters are Using Them | Digital for Pharma | Scoop.it

eMarketer has significantly revised its estimates of wearable-device users in the US. The still-young category showed early promise, but usage has not expanded beyond early adopters.

 

In October 2015, eMarketer expected usage among US adults to grow more than 60% this year. But according to its latest forecast, it will only grow 24.7%, as smart watches in particular have failed to impress consumers.

 

This year, 39.5 million US adults will use a wearable device (with internet connectivity) at least once a month, far less than the 63.7 million previously forecast. Smart watches haven’t caught on in large numbers, primarily because of their high price point and lack of definitive use case. This year, usage of wearables will reach just 15.8% of the population. That penetration rate is only expected to grow to 21.1% by 2020.

 

“Before Apple launched its Watch, fitness trackers dominated the wearables space, and consumer surveys consistently found that tracking health and fitness was the main reason people were interested in wearables,” said eMarketer analyst Cathy Boyle. “They also reported high price-sensitivity. Without a clear use case for smart watches—which have more features than fitness trackers, but significant overlap with smartphone functionality—the more sophisticated, expensive devices have not caught on as quickly as expected.”

 

Further reading:

“Why 2016 Will Be The Year Of Mass Wearables Adoption”: http://sco.lt/7tKbpJ [Ha! I guess they will have to rethink that prediction!]“Most Doctors Not Yet Ready to Recommend Mobile Apps & Wearable to Patients”: http://sco.lt/8yujoX“MIT/Harvard ‘Hackers’ Dis Pharma's mHealth & Wearable App Efforts”: http://sco.lt/91ET45
Via Pharma Guy
more...
Pharma Guy's curator insight, December 20, 2016 9:53 AM

This may be bad news for pharma companies hoping to use wearables in clinical trials. Read, for example, "AstraZeneca to Use Smart Blood Pressure Cuff & Mobile App in Clinical Trials"; http://sco.lt/5YFHVZ 

Rescooped by Claudio Bini from Digital Disruption in Pharma
Scoop.it!

Flowchart: How Pharma Can Handle Every Type of Comment on Social Media

Flowchart: How Pharma Can Handle Every Type of Comment on Social Media | Digital for Pharma | Scoop.it

For most -- not all -- pharma companies, engaging people via social media is a problem, which I have often written about. Actually, it's several problems: (1) regulatory issues, (2) side effect reporting issues, (3) off-label promotion issues, but, most importantly, IMHO, (4) resource issues. Therefore, most -- not all -- pharma companies have a simplified flowchart for dealing with positive, negative or neutral comments on social media, which probably looks like this one.


Via Pharma Guy
more...
Pharma Guy's curator insight, December 14, 2016 7:16 AM

Philippe Kirby (@PhilippeKirby), Pharma Customer Engagement Ecosystem designer & developer @ Merck & MSD, asked "Is this a joke?" I respect Philippe opinion and have interviewed him about the "near future" of digital pharma back in 2013 (listen here), so I should respond to his question & hopefully stimulate some further discussion.

Rescooped by Claudio Bini from Digital Disruption in Pharma
Scoop.it!

Association of the British #Pharma Industry Proposes a “Brexit” Social Media Policy for Its Members

Association of the British #Pharma Industry Proposes a “Brexit” Social Media Policy for Its Members | Digital for Pharma | Scoop.it

Pharma social media guidelines in the U.S. are starkly different, and more open, than in other countries around the world. But that doesn’t mean pharma is simply sitting out social in other regions. In the U.K., for instance, more pharma companies are now adopting country-specific social media.

 

Novartis, for one, recently launched a U.K.-specific Twitter account, and other pharma companies are also beginning to follow suit, according to U.K.-based PMLiVE.

 

The market for social media "in terms of pharma in the U.K. is almost completely different from the U.S.,” which necessitates the need for separate country channels, Andrew Ross, media relations manager of The Association of the British Pharmaceutical Industry, told FiercePharma in an interview.

 

As in general advertising, product-specific brand mentions are banned in U.K. social media—except to healthcare professionals who have specifically agreed to receive messages. Still, that shouldn’t—and generally today, doesn’t—stop social media activity.

 

“There’s not anything stopping pharmaceutical companies from using social media in the U.K. provided it’s done in a responsible way and in line with the code of practice,” Ross said. “... Spending more money in the U.K. on social media output is definitely one of those things that need to be done because the benefit can be so big."

 

But do pharma companies need different Twitter handles in different countries? Yes, he said, because different relationships between pharma companies and their audiences—healthcare professionals and consumers— in different countries need tailored messaging to be relevant.

 

“As a U.K. consumer, looking at a corporate-run U.S. account or corporate-run account from somewhere like Japan, I’m not sure that would resonate with me near as well as something that was U.K.-led,” Ross said.

 


Via Pharma Guy
more...
No comment yet.
Rescooped by Claudio Bini from Pharma Marketing News, Views & Events
Scoop.it!

FDA Compliant Diclegis Instagram Promo by (Good) Emily Maynard Johnson Can't Compete with (Bad) Kim Kardashian's Violative Post

FDA Compliant Diclegis Instagram Promo by (Good) Emily Maynard Johnson Can't Compete with (Bad) Kim Kardashian's Violative Post | Digital for Pharma | Scoop.it

About 22 weeks ago, Emily Maynard Johnson, who appeared on ABC's The Bachelor and The Bachelorette, posted a Diclegis promotion to her Instagram account (see above).I assume you've noticed that all the ISI (Important Safety Information) and side effects are mentioned either through links or, more importantly, within the post itself (you have to scroll down to see it).This is in contrast to Kim Kardashian's Diclegis Instagram promotion that made news last year. That ad drew a prompt warning letter from the FDA to Duchesnay USA, which markets the drug, because the post did not mention nor did it link to any ISI or side effect information as required by FDA regulations (for more on that read "OMG. Kim Kardashian Shills for Pharma! No Worry - No Side Effects!" and "Celebrities + Social Media"). There are a couple of other important differences between these two celebrity Instagram endorsements/ads.


Via Pharma Guy
more...
No comment yet.
Rescooped by Claudio Bini from PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
Scoop.it!

Bernie Sanders Just Embarrassed Big Pharma on Twitter

Bernie Sanders Just Embarrassed Big Pharma on Twitter | Digital for Pharma | Scoop.it

Though drug companies tend to justify high drug prices, in part, by citing investments in research and development, not everyone buys that argument.

In response to a tweet from the Pharmaceutical Research and Manufacturers of America (PhRMA), the top lobbying arm of the industry, which touted $58.8 billion in R&D spending in 2015, Sanders wrote: "Actually 89 out of the top 100 pharmaceutical corporations spent more on marketing and sales than on R&D."

He was referring to a 2014 report from the health care research firm GlobalData, which revealed how drug companies invest more on efforts to sell their products than innovate them. Take Johnson & Johnson, the world's largest pharmaceutical company, for example; in 2013, the company spent $17.5 billion on marketing and only $8.2 billion on research and development, BBC reported.

It's certainly true that research and development represents a costly investment that factors into drug prices, but some experts have raised questions about the extent to which R&D actually determines these prices given the disproportionate spending on marketing.


Via Pharma Guy, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Rescooped by Claudio Bini from Digital for Pharma
Scoop.it!

#FDA Publishes New Draft Guidance on Software as a Medical Device (SaMD).

#FDA Publishes New Draft Guidance on Software as a Medical Device (SaMD). | Digital for Pharma | Scoop.it

The FDA has entered into the federal register a new draft guidance pertaining to "software as a medical device" (SaMD). The guidance is presented as representing the FDA's current thinking on establishing clinical evaluation guidelines for SaMD, but is written by an international organization of device regulators, the International Medical Device Regulators Forum, of which FDA is a member.

The guidance seeks to articulate what's new and different about SaMD (a category which would include mobile medical apps) and provide a stratified guidance on how to regulate different kinds of software and what kind of evidence is needed for each regulatory category. The guidance stratifies devices on two axes: whether the device informs care, drives care, or treats/diagnoses and whether the condition in question is non-serious, serious, or critical. So software that treats or diagnoses a critical condition is in the highest risk category, while software that informs care about a non-serious condition is in the lowest.

The guidelines also call out and address the fact that software development tends to move faster than traditional medical device development and can more easily be influenced by postmarket data.

"SaMD ... is unique in that it operates in a complex highly connected-interactive socio-technical environment in which frequent changes and modifications can be implemented more quickly and efficiently," the guidance says. "Development of SaMD is also heavily influenced by new entrants unfamiliar with medical device regulations and terminology developing a broad spectrum of applications."


Via Pharma Guy, Lionel Reichardt / le Pharmageek, Claudio Bini
more...
Pharma Guy's curator insight, October 18, 2016 7:26 AM

Related article: “Is SaaD - Software as a Drug - the Next Big Thing in mHealth?”; http://sco.lt/7SITsv

rob halkes's curator insight, October 18, 2016 7:39 AM

Via @pharmaguy The New #FDA draft guidance on software as a Medical Device (SaMD)

Rescooped by Claudio Bini from Pharma Communication & Social Media
Scoop.it!

Nestle, Samsung to develop digital health platform

Nestle, Samsung to develop digital health platform | Digital for Pharma | Scoop.it

Nestle and Samsung have announced a research collaboration that will see the world's largest food maker team up with the Korean tech giant to explore the potential of nutrition science and digital sensor technologies. The long-term goal of the collaboration is to combine 'Internet of Things' technology with "breakthrough nutrition science". The companies are developing a new digital health platform to provide personalised recommendations around nutrition, lifestyle and fitness. Nestle and Samsung said their aim is to "empower people" to better manage their health and wellness using "one simple, connected entity".


Via Dinesh Chindarkar
more...
No comment yet.
Rescooped by Claudio Bini from PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
Scoop.it!

Multichannel in Healthcare: First Service, Then Channel

Multichannel in Healthcare: First Service, Then Channel | Digital for Pharma | Scoop.it

Britain’s conservative NHS cooperates with dating app Tinder, whilst big pharmaceutical companies cooperate with Google or Apple. And in spite of this, healthcare companies still struggle to make “multichannel” the new paradigm. Why is that? What becomes of the elaborate consultancy projects and costly investments in software and data? Flagship projects alone, it seems, are not enough to bring about change. And customers have long since overtaken companies. Here, even just simple principles can help to bring communication planning significantly closer to the doctor or patient. And thus, quite incidentally, to turn channel planning into service planning.


Via Olivier Delannoy, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Rescooped by Claudio Bini from Digital Disruption in Pharma
Scoop.it!

10+ of the Most Important Digital Health Incubators in Europe

10+ of the Most Important Digital Health Incubators in Europe | Digital for Pharma | Scoop.it

Speaking of digital health incubators, the names of industry pioneers like RockHealth and other US players pop into our minds without much prompting, but on a regional or local scale, which are the most important European incubator/accelerator programmes?Small European startups may seek development and growth support through an acceleration program but their CEOs might not even know what the best and most reliable companies in our continent are to contact. Fortunately, when it comes to digital health incubators, Europe can boast a substantial landscape today.Here’s the guide to the 10 most important startup support programmes in Europe in the area of digital health.


Via Pharma Guy
more...
Pharma Guy's curator insight, September 11, 2016 7:52 AM

Also read:

 

Rescooped by Claudio Bini from Pharma Marketing
Scoop.it!

How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA

How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA | Digital for Pharma | Scoop.it
“After a Facebook PR meltdown two years ago, Sanofi has emerged as a social media leader with a robust community for diabetics. Here's how the”
Via COUCH Medcomms
more...
No comment yet.
Rescooped by Claudio Bini from Digital Disruption in Pharma
Scoop.it!

How AstraZeneca Plans to Bring Medical Meetings to Everyone via Social Media

How AstraZeneca Plans to Bring Medical Meetings to Everyone via Social Media | Digital for Pharma | Scoop.it

For decades, medical meetings have been a place for doctors, patients, researchers and advocates to engage with each other and share information about the latest advances in treatments and science.

 

That engagement level has exploded over the last few years, however, with the rise of social media. Now, attendees can talk not only to others in the meeting hall but also in every corner of the globe.

 

How important has social media grown to become at medical meetings? Consider: The 2013 American Society of Clinical Oncology (ASCO) Annual Meeting saw 4,352 different people tweet 21,861 times using the #ASCO13 hashtag throughout the year. Two years later, the #ASCO15 meeting was mentioned in 81,273 tweets from 16,664 people – a nearly four-fold increase.

 

AstraZeneca once again will participate in major meetings in our therapeutic areas this year, including ASCO, AHA, ACC, ADA and several others. In addition to our live presence at the meetings, we hope to accomplish the following through our social engagement:

 

Conduct live, authentic dialogue with those in attendance as well as those following along virtually.Share our messages and resources with an informed, engaged audience.Continue conversations begun face to face in the meeting halls.Glean key areas of focus of those affected by the diseases being studied to better inform our efforts as a company.

 

It is increasingly crucial for all players in healthcare to be engaged in social media, as more and more Americans use these platforms.


Via Pharma Guy
more...
Pharma Guy's curator insight, June 28, 2016 7:15 AM

Astrazeneca has been a pioneer in hosting authentic Twitter chats. read, for example, “OMG! AstraZeneca Hosts Twitter Chat & World Does NOT End!”; http://bit.ly/AZpharmachat